Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Abajas, Yasmina
The Atlanta Study, NCT04030052: Emicizumab PUPs and Nuwiq ITI Study	Withdrawn	3	2	US	Nuwiq (low dose protocol), Simoctocog alfa, HEMLIBRA, Emicizumab, ACE910, and RO5534262, Nuwiq (Atlanta protocol)	Emory University, Genentech, Inc.	Hemophilia A	01/23	01/23
B-Natural, NCT02502409: Natural History Study of Factor IX Treatment and Complications	Active, not recruiting	N/A	550	US	Standard care with blood and urine sample collection	Skane University Hospital, Indiana Hemophilia &Thrombosis Center, Inc., Bioverativ Therapeutics Inc., Swedish Orphan Biovitrum	Factor IX Deficiency	06/19	12/21